Ornella Cantale

Dr. Ornella Cantale

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2020 in Clinical Lung Cancer
Verified
Journal Article
Closed access
ACAlessio Cortellini
Alessio Cortellini
AFAlex Friedlaender
Alex Friedlaender
Giuseppe BannaGiuseppe Banna
Giuseppe Banna
GPGiampiero Porzio
Giampiero Porzio
MBMelissa Bersanelli
Melissa Bersanelli
KCKatia Cannita
Katia Cannita

28 June 2022 in International Immunopharmacology
Verified
Journal Article
Open access
Giuseppe BannaGiuseppe Banna
Giuseppe Banna
OCOrnella Cantale
Ornella Cantale
SMSethupathi Muthuramalingam
Sethupathi Muthuramalingam
JCJudith Cave
Judith Cave
CCCharles Comins
Charles Comins
FGFabio Gomes
Fabio Gomes
Efficacy outcomes and prognostic factors of real-world patients with advanced non-small cell lung cancer (aNSCLC) treated with first-line chemoimmunotherapy are still limited. In the retrospective Spinnaker study, data was collected from patients in six United Kingdom and one Swiss oncology centres with first-line pembrolizumab plus platinum-based chemotherapy. Efficacy outcomes and potential prognostic factors were estimated aiming at developing a prognostic model. Three-hundred-eight patients were included, 32% ≥ 70 years, with ≥ 3 metastatic sites in 33%, brain or liver metastases in 10% and 12%, respectively. With a median follow-up of 18.0 months (mo.) (range, 15.9-20.1), median overall survival (OS) and progression-free survival (PFS) were 12.7 mo. (range, 10.2-15.2), and 8.0 mo. (range, 7.1-8.8), respectively. The neutrophils-to-lymphocytes ratio (NLR) and systemic immune-inflammatory index (SII) (i.e., NLR × platelet count) were both significantly higher in ECOG PS 1 (p = 0.0147 and p = 0.0018, respectively), underweight or normal body mass index (p = 0.0456 and p = 0.0062, respectively), ≥3 metastatic sites (p = 0.0069 and p = 0.112), pretreatment steroids (p = 0.0019 and p = 0.0017). By MVA, the number of metastatic sites ≥ 3 (p < 0.001 and p = 0.002), squamous histology (p = 0.033 and p = 0.013) and SII ≥ 1444 (p = 0.031 and p = 0.009, respectively) were associated with both worse OS and PFS and led to a highly discriminating three-class risk prognostic model. Real-world PFS with chemoimmunotherapy in aNSCLC patients is similar to that reported in clinical trials. A high number of metastatic sites, squamous histology and high SII are adverse prognostic factors that might contribute to a clinically useful prognostic model.

2 December 2023 in Expert Review of Respiratory Medicine
Verified
Journal Article
Closed access
AMAndrea Mogavero
Andrea Mogavero
OCOrnella Cantale
Ornella Cantale
VMVeronica Mollica
Veronica Mollica
SAShobana Anpalakhan
Shobana Anpalakhan
AAAlfredo Addeo
Alfredo Addeo
GBGiuseppe Luigi Banna
Giuseppe Luigi Banna
Immunotherapy (IO) has established a new milestone in lung cancer treatment. Several registrational studies have approved immune checkpoint inhibitors (ICIs) in different settings, including the metastatic nonsmall cell lung cancer (NSCLC). As wellknown, responders are just a certain proportion of patients, therefore their selection by using predictive factors has stood out as a crucial issue to address in tailoring a patientcentered care. In our review we propose a detailed yet handy cross section on ICIs as firstline treatment in metastatic NSCLC, regarding indications, histological, clinical and bloodbased biomarkers, other than their mechanisms of resistance and new immunological actionable targets. We performed a literature search through PubMed entering keywords complying with crucial features of immunotherapy. IO represents the backbone of lung cancer treatment. Trials are currently testing novel immune blockade agents assessing combinatorial approaches with standard ICIs, or antibody drug conjugates (ADC), harboring immunological targets. Perfecting patients' selection is an ongoing challenge and a more and more urgent need in order to best predict responders who will consistently benefit from it.

12 January 2021 in Journal of Molecular Pathology
Verified
Journal Article
Open access
PDF file
SCSalvatore Caponnetto
Salvatore Caponnetto
OCOrnella Cantale
Ornella Cantale
AFAlex Friedlaender
Alex Friedlaender
FGFabio Gomes
Fabio Gomes
SDSunil Daryanani
Sunil Daryanani
Giuseppe BannaGiuseppe Banna
Giuseppe Banna
Patients with non-small-cell lung cancer (NSCLC), harboring Epidermal Growth Factor Receptor (EGFR) mutations, are more susceptible to brain metastases (BM). Comparisons of the efficacy of different-generation EGFR-tyrosine kinase inhibitors (TKI) on BMs from NSCLC are currently limited. We identified studies comparing different EGFR-TKIs for NSCLC through Pubmed literature search and selected those with neurological outcome data. By two retrospective analyses, Erlotinib showed longer neurological time-to-progression (30 months vs. 15.8 months, P = 0.024) and reduced the risk of central nervous system (CNS) progression (Hazard Ratio (HR) 0.25; 95% CI, 0.08–0.81; P = 0.021) compared to Gefitinib. In a phase 2b randomized trial, 16% of patients with BMs had a similar Progression Free Survival (PFS) (HR 0.76, 95% CI 0.41–1.44) or Overall Survival (OS) (HR 1.16, 95% CI 0.61–2.21) with Afatinib versus Gefitinib; a lower risk of developing subsequent BMs with Afatinib than Gefitinib (HR 0.49; 95% CI 0.34–0.71; P < 0.001) was reported by a retrospective study. A randomized phase 3 trial proved that patients with BMs treated with Osimertinib had longer PFS (HR 0.47, 95% CI 0.30–0.74) and OS (HR 0.79, 95% CI 0.61–1.01) than with Gefitinib, and lower incidence of CNS progression (6% vs. 15%, respectively). Although there is limited evidence, differences in CNS activity may exist between EGFR-TKIs.

15 April 2025 in European Journal of Cancer
Verified
Journal Article
Closed access
FMFederico Monaca
Federico Monaca
MRMartín Igor Gómez-Randulfe Rodríguez
Martín Igor Gómez-Randulfe Rodríguez
APAna Sofia de Freitas Matos Parreira
Ana Sofia de Freitas Matos Parreira
VLVito Longo
Vito Longo
DGDomenico Galetta
Domenico Galetta
RCRaffaele Califano
Raffaele Califano

16 October 2025 in Lung Cancer
Verified
Journal Article
Closed access
IGIgor Gomez-Randulfe
Igor Gomez-Randulfe
FMFederico Monaca
Federico Monaca
OCOrnella Cantale
Ornella Cantale
Maria Lucia RealeMaria Lucia Reale
Maria Lucia Reale
LMLoredana Mrak
Loredana Mrak
RCRaffaele Califano
Raffaele Califano